Search Browse Earnings

Mineralys Therapeutics, Inc. — SlamSEC

Mineralys Therapeutics, Inc.

Nasdaq:MLYS

Pharmaceutical Preparations·RADNOR, PA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$84.7M

FY 2024

Net Income

-$71.9M

FY 2024

EPS (Diluted)

-$1.99

FY 2024

Stock Price

$28.40

+4.3%

2026-03-10

52W Range

$10.44 – $47.65

P/E Ratio

-14.3x

Market Cap

$2.2B

Cash

$49.3M

FY 2024

Total Debt

—

Net Cash

$49.3M

Enterprise Value

$2.2B

Debt / EBITDA

0.6x

FY 2024

EV / EBITDA

-26.0x

Employees

—

CEO

Congleton Jon